rs1064794282
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000138.5(FBN1):c.2243G>A(p.Cys748Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C748R) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000138.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Marfan syndrome Pathogenic:2
- -
The FBN1 c.2243G>A variant has been reported in individuals affected with Marfan syndrome (Katzke et. al., 2002; Hung et. al., 2009) and one or more missense substitutions at this codon (p.Cys748Tyr and p.Cys748Arg) in affected individuals suggests that this may be a clinically significant residue (Hung CC et. al., 2009; Becerra-Muñoz VM et. al., 2018). This variant affects a cysteine residue in the EGF-like, TGFBP or hybrid motif domains FBN1. Cysteine residues are believed to be involved in intramolecular disulfide bridges and have been shown to be important for FBN1 protein structure (Mellody et. al., 2006; Ono RN et. al., 2009). In addition, missense substitutions affecting cysteine residues within these domains are significantly overrepresented among patients with Marfan syndrome (Robinson PN et. al., 2006; Katzke et. al., 2002). The p.Cys748Tyr variant is novel (not in any individuals) in gnomAD Exomes and 1000 Genomes. This variant has been reported to the ClinVar database (Pathogenic/Likely Pathogenic). The amino acid Cys at position 748 is changed to a Tyr changing protein sequence and it might alter its composition and physico-chemical properties. The amino acid change p.Cys748Tyr in FBN1 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:2
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Affects a cysteine residue within a calcium-binding EGF-like domain of the FBN1 gene, which may affect disulfide bonding and is predicted to alter the structure and function of the protein; cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with FBN1-related disorders (Collod-Beroud et al., 2003); This variant is associated with the following publications: (PMID: 26770496, 28391405, 30675029, 19328768, 12203992, 12161601, 12938084, 31830381, 37203318, 19839986) -
PS4_moderate, PM1, PM5, PP3, PP4, PM2_supporting -
Marfan Syndrome/Loeys-Dietz Syndrome/Familial Thoracic Aortic Aneurysms and Dissections Pathogenic:1
Variant summary: FBN1 c.2243G>A (p.Cys748Tyr) results in a non-conservative amino acid change located in the EGF-like domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251436 control chromosomes. c.2243G>A has been reported in the literature in multiple individuals affected with Marfan Syndrome (e.g. Katzke_2002, Hung_2009, Xu_2019). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. However, this variant disrupts one of the cysteine residues in the EGF-like domain, which are known to play an important role in protein structure and interactions with other molecules, suggesting that the variant could affect protein function (e.g. Dietz_1992). Two other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both laboratories cited the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
The observation of one or more missense substitutions at this codon (p.Cys748Tyr and p.Cys748Arg) in affected individuals suggests that this may be a clinically significant residue (PMID: 19839986, 29357934). This variant affects a cysteine residue in the EGF-like, TGFBP or hybrid motif domains FBN1. Cysteine residues are believed to be involved in intramolecular disulfide bridges and have been shown to be important for FBN1 protein structure (PMID: 16905551, 19349279). In addition, missense substitutions affecting cysteine residues within these domains are significantly overrepresented among patients with Marfan syndrome (PMID: 16571647, 17701892). For these reasons, this variant has been classified as Pathogenic. This variant has been observed in individuals affected with Marfan syndrome (PMID: 12203992, 19839986, 12161601, 26770496). ClinVar contains an entry for this variant (Variation ID: 420086). This variant is not present in population databases (ExAC no frequency). This sequence change replaces cysteine with tyrosine at codon 748 of the FBN1 protein (p.Cys748Tyr). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and tyrosine. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at